Research programme: tyrosine kinase inhibitors - Ascepion Pharmaceuticals

Drug Profile

Research programme: tyrosine kinase inhibitors - Ascepion Pharmaceuticals

Alternative Names: ASP-08001; ASP-08112; ASP-502D

Latest Information Update: 19 Jun 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ascepion Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 19 Jun 2012 Preclinical development is ongoing in China
  • 21 Apr 2010 Preclinical trials in Solid tumours in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top